Senate Bill 977
116th Congress(2019-2020)
Transparent Drug Pricing Act of 2019
Introduced
Introduced in Senate on Apr 1, 2019
Origin Chamber
Senate
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
977
Congress
116
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
No Senate votes have been held for this bill.
Summary
Transparent Drug Pricing Act of 2019
This bill establishes several requirements relating to the prices of prescription drugs.
For example, state Medicaid drug-use review programs must require pharmacists to disclose an individual's out-of-pocket cost for a prescription drug, and the price without health insurance, at the point-of-sale. Additionally, health insurers must publish the co-payment amount for each covered prescription drug prior to the annual open-enrollment period.
The bill also temporarily prohibits the retail list price of drugs and biologics from exceeding the lowest retail list price among Canada, France, the United Kingdom, Japan, or Germany.
April 1, 2019
04/01/2019
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
04/01/2019
Introduced in Senate
Public Record
Record Updated
Nov 1, 2022 6:47:25 PM